FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4250263171> ?p ?o ?g. }

• W4250263171 abstract "Lesch-Nyhan disease (LND) is a rare X-linked genetic disorder, with complete hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency, uric acid (UA), hypoxanthine and xanthine accumulation, and a devastating neurologic syndrome. UA excess, causing renal failure, is commonly decreased by xanthine oxidoreductase (XOR) inhibitors, such as allopurinol, yielding a xanthine and hypoxanthine increase. Xanthine accumulation may result in renal stones, while hypoxanthine excess seems involved in the neurological disorder. Inhibition of purine nucleoside phosphorylase (PNP) represents a different strategy for lowering urate. PNP catalyzes the cleavage of purine ribo- and d-ribo-nucleosides into ribose/deoxyribose phosphate and free bases, starting catabolism to uric acid. Clinical trials demonstrated that PNP inhibitors, initially developed as anticancer drugs, lowered UA in some gouty patients, in association or not with allopurinol. The present study tested the reliability of an analogue of immucillin-G (C1a), a PNP inhibitor, as a therapy for urate, hypoxanthine, and xanthine excess in LND patients by blocking hypoxanthine production upstream. The therapeutic aim is to limit the administration of XOR inhibitors to LND patients by supplying the PNP inhibitor in low doses, avoiding d-nucleoside toxicity. We report studies conducted in primary cultures of skin fibroblasts from controls and LND patients grown in the presence of the PNP inhibitor. Cell viability, oxypurine release in culture medium, and endocellular nucleotide pattern have been monitored in different growth conditions (inhibitor concentration, time, added inosine). Our results demonstrate effective PNP inhibition by low inhibitor concentration, with reduced hypoxanthine release, and no appreciable toxicity in control or patient cells, suggesting a new therapeutic strategy for LND hyperuricemia." @default.
• W4250263171 created "2022-05-12" @default.
• W4250263171 creator A5013308614 @default.
• W4250263171 creator A5021170470 @default.
• W4250263171 creator A5023098877 @default.
• W4250263171 creator A5061059547 @default.
• W4250263171 creator A5069455103 @default.
• W4250263171 creator A5091423910 @default.
• W4250263171 date "2018-06-04" @default.
• W4250263171 modified "2023-09-27" @default.
• W4250263171 title "Inhibiting PNP for the therapy of hyperuricemia in Lesch-Nyhan disease: preliminary in vitro studies with analogues of immucillin-G" @default.
• W4250263171 cites W1481890255 @default.
• W4250263171 cites W1994066783 @default.
• W4250263171 cites W2006614634 @default.
• W4250263171 cites W2013665948 @default.
• W4250263171 cites W2018124448 @default.
• W4250263171 cites W2022889821 @default.
• W4250263171 cites W2024390232 @default.
• W4250263171 cites W2030603509 @default.
• W4250263171 cites W2042945532 @default.
• W4250263171 cites W2050527189 @default.
• W4250263171 cites W2050926182 @default.
• W4250263171 cites W2072883404 @default.
• W4250263171 cites W2080668081 @default.
• W4250263171 cites W2094080430 @default.
• W4250263171 cites W2097650890 @default.
• W4250263171 cites W2104419050 @default.
• W4250263171 cites W2112331260 @default.
• W4250263171 cites W2123542580 @default.
• W4250263171 cites W2144635750 @default.
• W4250263171 cites W2293571729 @default.
• W4250263171 cites W240912721 @default.
• W4250263171 cites W2558132143 @default.
• W4250263171 cites W2614191860 @default.
• W4250263171 cites W2624517231 @default.
• W4250263171 cites W4232049465 @default.
• W4250263171 doi "https://doi.org/10.1007/s10545-018-0196-x" @default.
• W4250263171 hasPublicationYear "2018" @default.
• W4250263171 type Work @default.
• W4250263171 citedByCount "1" @default.
• W4250263171 countsByYear W42502631712018 @default.
• W4250263171 crossrefType "journal-article" @default.
• W4250263171 hasAuthorship W4250263171A5013308614 @default.
• W4250263171 hasAuthorship W4250263171A5021170470 @default.
• W4250263171 hasAuthorship W4250263171A5023098877 @default.
• W4250263171 hasAuthorship W4250263171A5061059547 @default.
• W4250263171 hasAuthorship W4250263171A5069455103 @default.
• W4250263171 hasAuthorship W4250263171A5091423910 @default.
• W4250263171 hasBestOaLocation W42502631711 @default.
• W4250263171 hasConcept C104317684 @default.
• W4250263171 hasConcept C126322002 @default.
• W4250263171 hasConcept C143065580 @default.
• W4250263171 hasConcept C181199279 @default.
• W4250263171 hasConcept C185592680 @default.
• W4250263171 hasConcept C2776476023 @default.
• W4250263171 hasConcept C2777610669 @default.
• W4250263171 hasConcept C2777991568 @default.
• W4250263171 hasConcept C2778939600 @default.
• W4250263171 hasConcept C2779470414 @default.
• W4250263171 hasConcept C2779721657 @default.
• W4250263171 hasConcept C2779881121 @default.
• W4250263171 hasConcept C2780261098 @default.
• W4250263171 hasConcept C2780402116 @default.
• W4250263171 hasConcept C2781116151 @default.
• W4250263171 hasConcept C2909697302 @default.
• W4250263171 hasConcept C55493867 @default.
• W4250263171 hasConcept C71615608 @default.
• W4250263171 hasConcept C71924100 @default.
• W4250263171 hasConcept C78179603 @default.
• W4250263171 hasConcept C98274493 @default.
• W4250263171 hasConceptScore W4250263171C104317684 @default.
• W4250263171 hasConceptScore W4250263171C126322002 @default.
• W4250263171 hasConceptScore W4250263171C143065580 @default.
• W4250263171 hasConceptScore W4250263171C181199279 @default.
• W4250263171 hasConceptScore W4250263171C185592680 @default.
• W4250263171 hasConceptScore W4250263171C2776476023 @default.
• W4250263171 hasConceptScore W4250263171C2777610669 @default.
• W4250263171 hasConceptScore W4250263171C2777991568 @default.
• W4250263171 hasConceptScore W4250263171C2778939600 @default.
• W4250263171 hasConceptScore W4250263171C2779470414 @default.
• W4250263171 hasConceptScore W4250263171C2779721657 @default.
• W4250263171 hasConceptScore W4250263171C2779881121 @default.
• W4250263171 hasConceptScore W4250263171C2780261098 @default.
• W4250263171 hasConceptScore W4250263171C2780402116 @default.
• W4250263171 hasConceptScore W4250263171C2781116151 @default.
• W4250263171 hasConceptScore W4250263171C2909697302 @default.
• W4250263171 hasConceptScore W4250263171C55493867 @default.
• W4250263171 hasConceptScore W4250263171C71615608 @default.
• W4250263171 hasConceptScore W4250263171C71924100 @default.
• W4250263171 hasConceptScore W4250263171C78179603 @default.
• W4250263171 hasConceptScore W4250263171C98274493 @default.
• W4250263171 hasLocation W42502631711 @default.
• W4250263171 hasOpenAccess W4250263171 @default.
• W4250263171 hasPrimaryLocation W42502631711 @default.
• W4250263171 hasRelatedWork W1594569184 @default.
• W4250263171 hasRelatedWork W1976847498 @default.
• W4250263171 hasRelatedWork W1983094030 @default.
• W4250263171 hasRelatedWork W2003407110 @default.
• W4250263171 hasRelatedWork W2010359857 @default.
• W4250263171 hasRelatedWork W2033824617 @default.

• next